Holiday Notice: Due to the observation of Memorial Day 2017, orders placed after 2:00pm EST on Friday, May 26 will not be shipped until Tuesday, May 30.
CBD CLINIC Professional Series topical medications are the first and only non-prescription ointments and creams that combine FDA-approved active ingredients and hemp extract (CBD). Our Revolutionary Pain Relief products are formulated with natural emollients to help active analgesic compounds penetrate deep to quickly increase blood flow to joints and muscles and interrupt pain signaling.
Each formula has three (3) foundational components for supporting rapid and lasting relief from joint and muscle pain, associated with daily living, sports injuries, arthritis, sprains, bruises and related types of inflammation:
The base formulations of our ointments and creams are made with all-natural emollients that are readily absorbed by human skin. CBD CLINIC emollients include organic beeswax, jojoba seed oil, cottonseed oil, and shea butter. These were selected and combined via a proprietary method which quickly delivers pain-relieving ingredients into the skin.
Comparatively, many other topical analgesic products use cheap, synthetic ingredients for their base, including benzyl alcohol, cetyl alcohol, diglycol stearate, glyceryl monostearate, petrolatum, etc.
In the mid-1990s, discovery of the endocannabinoid enabled a major breakthrough in new therapies for reducing pain, inflammation and other ailments. The endocannabinoid system is a group of endogenous cannabinoid receptors located in the mammalian brain and throughout the central and peripheral nervous systems, consisting of neuromodulatory lipids and their receptors.
The endocannabinoid receptor system plays a significant role in regulating neurotransmitter function. One receptor that is being actively studied is called CB1. It is found in spinal and peripheral nervous tissue (including areas important for pain perception). Although research into modulation of the endocannabinoid system is still in its early phases, studies published in the British Journal of Pharmacology and elsewhere have reported that some terpenes have been identified as having allosteric modulator properties, capable of slowing down neurotransmitter signaling. These findings help us understand the therapeutic relevance and benefits that terpenes may have with pain perception and how they can support reductions in pain.